Fresenius Medical Care (FME) has collaborated with Mexico’s Coordination of National Institutes of Health and Specialty Hospitals (CCINSHAE) to extend high-volume haemodiafiltration (HighVolumeHDF) access to individuals.
This initiative aims to develop a pilot programme that offers low-income individuals with no medical coverage in Mexico with haemodialysis therapies.
Under a two-year contract, 150 of FME’s 5008S CorDiax systems will be installed across participating renal treatment centres within CCINSHAE Centers in Mexico City and its metropolitan region.
This technology offers both standard haemodialysis and HighVolumeHDF, which have been shown to enhance patient well-being.
The collaboration has already offered HighVolumeHDF treatment to 240 new CCINSHAE patients who lack public or private medical insurance.
Last year, 410 insured patients started receiving HighVolumeHDF.
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataFME Mexico care enablement commercial operations managing director Edgar Robles said: 鈥淭he groundbreaking pilot programme, with its mission to provide chronic kidney disease (CKD) patients with access to high-quality treatments that were previously out of their reach, represents an important advancement in CKD in Mexico.鈥�
HighVolumeHDF is supported by various clinical studies, including the CONVINCE trial, which reported a 23% average decrease in all-cause death for HighVolumeHDF patients against those receiving standard high-flux haemodialysis.
FME currently offers HighVolumeHDF therapy across several countries in the Americas and plans to introduce it in the US for kidney disease patients.
In February 2024,聽the company secured the US Food and Drug Administration (FDA) 510(k) clearance for its 5008X Hemodialysis System.
The updated version of the new haemodiafiltration-capable 5008X CAREsystem with additional features also received 501(k) clearance earlier this year.
Last month, the company began the US commercialisation of the system for high-volume HDF kidney replacement therapy.
